The Ubrelvy and Qulipta Pregnancy Exposure Registry EMPRESS: An Observational, Prospective Study to Assess the Safety of Ubrelvy (Ubrogepant) and Qulipta (Atogepant) During Pregnancy
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine
- Focus Adverse reactions
- Acronyms EMPRESS
- Sponsors Allergan
Most Recent Events
- 13 Jan 2025 Planned End Date changed from 29 Sep 2034 to 1 Sep 2034.
- 13 Jan 2025 Planned primary completion date changed from 29 Sep 2034 to 1 Sep 2034.
- 05 Apr 2024 Planned number of patients changed from 1120 to 1884.